MOTS-c Results Timeline: What Studies Measured, and When

Answer first: the MOTS-c timeline literature is preclinical

Questions about how quickly MOTS-c "works" assume a body of human trials that reported outcomes at fixed intervals — four weeks, eight weeks, twelve weeks. That body of work does not exist for MOTS-c. A 2026 narrative review in Sports Medicine examined approved and unapproved peptide therapies used in the context of musculoskeletal injury and athletic performance and placed mitochondrial-derived peptides in the unapproved category, without clinical efficacy data to support performance claims (PMID 41966639). Everything else summarised below comes from laboratory models — rodents, surgical injury preparations and cultured cells — where the clock runs on the experiment's design, not on a person's calendar.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions. It describes what was measured, in which model, and at what stage of that model. It states no doses and no schedules, because those details belong to the methods sections of the individual papers rather than to a summary page.

Three timeline shapes in the MOTS-c literature

Preclinical MOTS-c studies fall into three broad design patterns, and each pattern produces a different kind of "timeline." Recognising the pattern is more useful than memorising an interval, because the interval is an artefact of the model.

1. Acute-insult models: endpoints anchored to a single event

In these designs the experimental clock starts at a defined injury and readouts follow within the same experimental window. Researchers reported that MOTS-c attenuated lung ischemia–reperfusion injury through MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (PMID 40403491). A separate study in a cardiopulmonary bypass–induced lung injury model reported that MOTS-c promoted glycolysis through an AMPK–HIF-1α–PFKFB3 pathway and ameliorated the resulting lung injury (PMID 40035775). In an Autophagy report, MOTS-c ameliorated lysosomal membrane permeability and improved survival of soft tissue transplantation (PMID 42153537). The "result" in these experiments is measured relative to reperfusion, bypass or grafting — not relative to a course of administration.

2. Injury-with-latency models: radiation lung work

Radiation injury studies build in a delay by nature, because lung damage develops after exposure. The study of radiation pneumonitis reported that MOTS-c alleviated the condition through an Nrf2-dependent mechanism (PMID 38790718). A related line of work reported that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner, treating the peptide as a required mediator rather than the administered agent (PMID 39259217). A 2026 Redox Biology paper reported that an engineered analogue, R13A-MOTS-c delivered via LAT1, attenuated radiation-induced lung injury through Nrf2 activation and mitochondrial protection (PMID 42142418). In this family the measured endpoint sits downstream of an exposure, so any apparent "onset" reflects the biology of radiation injury as much as the peptide.

3. Chronic-disease models: repeated administration, later readouts

Metabolic and degenerative models are the closest analogue to a multi-week timeline. Researchers reported that MOTS-c relieved hyperglycemia and insulin resistance in gestational diabetes mellitus (PMID 34798268). In cardiac work, one study reported that MOTS-c restored mitochondrial respiration in the type 2 diabetic heart (PMID 40661667), while another reported that MOTS-c regulated the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy (PMID 39616938). In joint tissue, a 2025 Free Radical Biology & Medicine report described MOTS-c attenuating mitochondrial dysfunction–induced pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism (PMID 41043625). An infection model in Gut reported a role for MOTS-c in mitochondrial remodelling that contributed to an antiviral effect during hepatitis B virus infection (PMID 37788894).

Study map: model, endpoint domain, and what the citation establishes

Why molecular endpoints appear before functional ones

Across these papers, the earliest measurable changes were molecular: transcriptional activation of antioxidant genes (PMID 40403491), pathway-level signalling through AMPK–HIF-1α–PFKFB3 (PMID 40035775) and Nrf2-dependent responses (PMID 38790718). Structural and functional endpoints — cartilage integrity (PMID 41043625), mitochondrial respiration in diabetic cardiac tissue (PMID 40661667) or graft survival (PMID 42153537) — require tissue to change, which takes longer in any model. That ordering is a general property of experimental biology, not a schedule that transfers to people.

What a week-by-week human expectation would require

To describe results at four, eight or twelve weeks, the literature would need controlled human trials with pre-registered endpoints, repeated measurements at those intervals, and a comparison group. The Sports Medicine review that surveyed peptide therapies in musculoskeletal and performance settings reported that many circulating peptides, including unapproved ones, lack this evidence base in humans (PMID 41966639). Until such trials are published and replicated, any week-by-week MOTS-c chart is extrapolation from animal models rather than a description of measured human outcomes.

Cross-model consistency is not the same as a timeline

One reason MOTS-c attracts attention is that similar mechanisms recurred across unrelated models. Nrf2-linked antioxidant responses were reported in radiation pneumonitis (PMID 38790718), in an engineered-analogue radiation lung study (PMID 42142418) and in osteoarthritic cartilage (PMID 41043625). Mitochondrial endpoints recurred in radiation-induced lung injury (PMID 39259217), the diabetic heart (PMID 40661667) and hepatitis B infection (PMID 37788894). Mechanistic consistency supports continued investigation; it does not establish when, or whether, a comparable change would register in a person.

Adverse Events and Timeline Reporting: What Studies Report

The preclinical papers listed here were designed around disease endpoints rather than tolerability surveillance, so they do not function as safety-timeline data. In the human-facing literature, the 2026 Sports Medicine review addressed safety alongside efficacy for approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance, and reported that unapproved agents are used without the regulatory and monitoring framework that accompanies approved products (PMID 41966639). No verified paper on this page reported a catalogue of adverse events in humans over defined weeks, and this page does not infer one.

Reading timeline claims critically

• Ask what event the clock started from. In ischemia–reperfusion work the reference point was the reperfusion insult (PMID 40403491), not a course of administration.
• Separate mediator studies from administration studies. One report used pyrroloquinoline quinone and found the protective effect was MOTS-c-dependent, which is a mechanistic dependency claim rather than a MOTS-c administration result (PMID 39259217).
• Note engineered analogues. The LAT1-delivered R13A-MOTS-c study tested a modified peptide with a delivery strategy, so its findings are not interchangeable with native MOTS-c (PMID 42142418).
• Check the species and disease context. Findings in gestational diabetes models (PMID 34798268) and diabetic cardiomyopathy models (PMID 39616938) describe diseased tissue, not healthy physiology.

Related reading

For background on what MOTS-c is, where it is encoded and how researchers describe its biology, see the overview at PeptideU's MOTS-c learn page.

References

• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)
• MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury (American Journal of Respiratory Cell and Molecular Biology, 2025)
• Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart (Frontiers in Physiology, 2025)
• MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy (Biochemical and Biophysical Research Communications, 2024)
• LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection (Redox Biology, 2026)
• MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation (Autophagy, 2026)
• The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism (Antioxidants, 2024)